The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury
Open accessAbstract
The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC chemokine receptor 1 (CXCR1) and CXCR2. Here we characterize the unique mode of action of a small-molecule inhibitor (Repertaxin) of CXCR1 and CXCR2. Structural and biochemical data are consistent with a noncompetitive allosteric mode of interaction between CXCR1 and Repertaxin, which, by locking CXCR1 in an inactive conformation, prevents signaling. Repertaxin is an effective inhibitor of polymorphonuclear cell recruitment in vivo and protects organs against reperfusion injury. Targeting the Repertaxin interaction site of CXCR1 represents a general strategy to modulate the activity of chemoattractant receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,429
Rollins, B. J. (1997) · Blood · doi:10.1182/blood.v90.3.909 · Cited by 1,984
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., & Power, C. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01439-x · Cited by 1,817
Gerard, C., & Rollins, B. J. (2001) · Nature Immunology · doi:10.1038/84209 · Cited by 1,357
DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1
Ojo, A. O., Wolfe, R. A., Held, P. J., Port, F. K., & Schmouder, R. L. (1997) · Transplantation · doi:10.1097/00007890-199704150-00011 · Cited by 989
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
The chemokine system: redundancy for robust outputs
Mantovani, A. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01469-3 · Cited by 704
Self-citationRollins, B. J. (1997) · PubMed · Cited by 603
White, J. R., Lee, J. M., Young, P. R., Hertzberg, R. P., Jurewicz, A. J., Chaikin, M. A., Widdowson, K., Foley, J. J., Martin, L. D., Griswold, D. E., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10095 · Cited by 432
Cited by
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Self-citationTumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Teijeira, Á., Garasa, S., Gato, M., Alfaro, C., Migueliz, I., Cirella, A., de Andrea, C., Ochoa, M. C., Otano, I., Etxeberria, I., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.001 · Cited by 788
Self-citationCXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 747
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
Russo, R. C., Garcia, C. C., Teixeira, M. M., & Amaral, F. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.894886 · Cited by 647
Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation
Viola, A., & Luster, A. D. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.121806.154841 · Cited by 583
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Neutrophils in cancer: prognostic role and therapeutic strategies
Ocana, A., Nieto-Jiménez, C., Pandiella, A., & Templeton, A. J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0707-7 · Cited by 459
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Alfaro, C., Sanmamed, M. F., Rodríguez-Ruiz, M. E., Teijeira, Á., Oñate, C., González, Á., Ponz, M., Schalper, K. A., Pérez-Gracia, J. L., & Melero, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.004 · Cited by 372
Chemokines: Integrators of Pain and Inflammation
White, F. A., Bhangoo, S. K., & Miller, R. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1852 · Cited by 280
The functional significance behind expressing two IL–8 receptor types on PMN
Stillie, R., Farooq, S. M., Gordon, J. R., & Stadnyk, A. W. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208125 · Cited by 272
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256
Chemokines and chemokine receptors: an overview
Bonecchi, R. (2009) · Frontiers in Bioscience · doi:10.2741/3261 · Cited by 255
CXCR2 antagonists for the treatment of pulmonary disease
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214
Enzmann, G., Kargaran, S., & Engelhardt, B. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418794184 · Cited by 119
Functional role of chemokines in liver disease models
Sahin, H., Trautwein, C., & Wasmuth, H. E. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.168 · Cited by 107
Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures
De Paola, M., Buanne, P., Biordi, L., Bertini, R., Ghezzi, P., & Mennini, T. (2007) · NeuroImmunoModulation · doi:10.1159/000123834 · Cited by 47
Bedolla, A., Taranov, A., Luo, F., Wang, J., Turcato, F., Fugate, E. M., Greig, N. H., Lindquist, D. M., Crone, S. A., Goto, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02367-w · Cited by 25
Metadata
- Authors
- Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M. N., Di Cioccio, V., Cesta, M. C., Galliera, E., Martinez, F. O., Di Bitondo, R., Troiani, G., Sabbatini, V., D'Anniballe, G., Anacardio, R., Cutrin, J. C., Cavalieri, B., Mainiero, F., Strippoli, R., Villa, P., Di Girolamo, M., Martin, F., Gentile, M., Santoni, A., Corda, D., Poli, G., Mantovani, A., Ghezzi, P., & Colotta, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-07-28
- Volume
- 101
- Issue
- 32
- Pages
- 11791-11796
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2136836360
- Cited by
- 333
- References
- 27
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.